Vera-Badillo, Francisco

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G., et al. (2019) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 1,633

Impact of Spin in the Abstracts of Articles Reporting Results of Randomized Controlled Trials in the Field of Cancer: The SPIIN Randomized Controlled Trial

Boutron, I., Altman, D. G., Hopewell, S., Vera-Badillo, F., Tannock, I., & Ravaud, P. (2014) · Journal of Clinical Oncology

Meta-analysis and systematic reviewsPharmaceutical industry and healthcare

Cited by 368

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Chi, K. N., Rathkopf, D., Smith, M. R., Efstathiou, E., Attard, G., Olmos, D., Lee, J. Y., Small, E. J., Pereira de Santana Gomes, A. J., Roubaud, G., et al. (2023) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 355

Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer

Vera-Badillo, F. E., Shapiro, R., Ocana, A., Amir, E., & Tannock, I. F. (2013) · Annals of Oncology

Meta-analysis and systematic reviewsStatistical Methods in Clinical Trials

Cited by 117

Benefit and harms of new anti-cancer drugs

Vera-Badillo, F. E., Al-Mubarak, M., Templeton, A. J., & Amir, E. (2013) · Current Oncology Reports

Statistical Methods in Clinical TrialsHealth Systems, Economic Evaluations, Quality of Life

Cited by 35